This morning, Dr. Rossana Chahla held a meeting with Dr. Víctor Zimmerman and Dr. Conrado Llapur, to discuss a research project to be carried out at the private institution on a new vaccine against COVID-19.
In this regard, the head of the health portfolio, said: “We are proud to have the visit of Dr. Víctor Zimmerman, who is the director of the Mayo Clinic, with a long history and very recognized. And today we can say that together with the director of Research in the province, Dr. Conrado Llapur, his clinic was selected to test a vaccine that has to do with COVID. “
In this sense, the official said that it is a pride that a clinic in the province was selected for this project, because meeting all the requirements to apply to this trial involved hard work by professionals.
“I am very happy to receive the visit, they told me that 48 hours ago they informed them that from a very few days they will begin to carry out this Phase 3 trial, of a vaccine that comes from a natural component. Thank you, make ourselves available. The collaboration of the public and private is very important, and it is being so at this time of pandemic since we can support both the public and private systems the same number of patients who require us, need us, “he stressed.
Later, the director of the Mayo Clinic thanked the minister for her words and said that this undertaking began four years ago with the Research department, which is headed by Dr. Conrado Llapur.
“You get to the results by walking and showing results. They definitely considered us because we are carrying out many research projects, they have been auditing us permanently, because this type of project is not done indiscriminately. They follow very strict protocols and have been audited by the laboratories and all the bodies that regulate these research protocols. We are very proud, ”he said.
Dr. Conrado Llapur explained that this Phase 3 project for the COVID-19 vaccine is designed to be carried out in 30 thousand volunteers around the world. It is carried out by the Canadian Medicago laboratory.
“What is particular about this vaccine is that particles similar to the virus protein are generated in plants. It is a technology that they are using in influenza vaccines as well. Phases 1 and 2 gave provisional results with a good level of neutralizing antibodies, with which phase 3 was approved to begin. Argentina is within one of the five Latin American countries that were selected with Brazil, Colombia, Mexico and Peru. Within Argentina it is a pride that Tucumán can participate in this trial through the Mayo Clinic ”, he explained.
The study authorized in the country will include patients from two populations: over 18 years of age up to and including 59 years of age, healthy or with comorbidities. They cannot have received a prior COVID vaccine in any study, they cannot have had COVID, and women do not have to be pregnant.
Pre-registration to be a volunteer is done through the Mayo Clinic page (https://clinicamayo.com.ar/) where a form is completed. “It is already approved by ANMAT, we are waiting for the vaccines to enter in order to start. In a short time we will begin to appoint patients, which we estimate will be a significant number, “he concluded.
Photo gallery
–
